Anti-Rat CD4 (Clone OX-38) – Purified in vivo PLATINUM™ Functional Grade

Clone OX-38 is a monoclonal antibody that specifically targets the rat CD4 antigen. While it is not commonly used in mice due to its specificity for rat CD4, its applications in rats can inform potential analogous uses in mice with species-specific CD4 antibodies. In rats, OX-38 is used for:

• In Vivo CD4+ T Cell Depletion: It has been used to deplete CD4+ T cells in vivo, which can be crucial for studying immune responses and tolerance.
• Induction of Allograft Unresponsiveness: Injection of OX-38 mAb can induce unresponsiveness to allografts (transplants from genetically different individuals), though results vary by rat strain.
• In Vitro Depletion of T Helper Cells: It has been used to deplete T helper cells from slice cultures in vitro.

If a similar antibody were used in mice, such as one targeting mouse CD4 (e.g., YTS 177 clone), it could be applied for analogous purposes like:

• In Vivo CD4+ T Cell Depletion: Blocking or depleting CD4+ T cells to study immune responses.
• Immune Response Modulation: Studying allograft tolerance or other immune responses in a mouse model.

However, specific applications for OX-38 in mice would not be directly relevant due to its rat-specificity.

Based on the available search results, there is limited specific information about antibodies commonly used alongside OX-38 in experimental studies. However, the search results do provide some relevant context about related antibodies and the CD4 research landscape.

Related CD4 Antibodies

The W3/25 antibody is closely related to OX-38, as both antibodies bind to the same epitope on the CD4 antigen. This suggests that W3/25 would be used in similar experimental contexts, though they would compete for binding rather than being used simultaneously. In contrast, the OX-35 antibody recognizes a different epitope on CD4 than OX-38, which could make it suitable for use in combination experiments or for targeting different functional aspects of the CD4 molecule.

Isotype Controls

For flow cytometry applications using OX-38, researchers commonly employ appropriate isotype controls. The Mouse IgG2a, κ isotype control is specifically recommended for use with OX-38, as it matches the antibody's isotype. This control is essential for determining background staining levels and ensuring accurate interpretation of flow cytometry data.

Functional Context

OX-38 is primarily used to identify and deplete CD4-expressing cells, including T helper cells, monocytes, and macrophages in rat models. Given its role in studying immune responses, it would likely be used alongside other T cell markers and immune cell antibodies, though the specific combinations are not detailed in the available literature.

The search results indicate that while OX-38 is well-characterized for its binding properties and applications, comprehensive information about commonly paired antibodies in published studies is not readily available in these sources.

Clone OX-38 is a mouse monoclonal antibody targeting rat CD4, cited extensively in immunological research primarily for its role in depleting or detecting CD4 T cells in rat models. The key findings from scientific literature that cite clone OX-38 are:

• CD4 T Cell Depletion: OX-38 is widely used to selectively deplete CD4+ T cells in rats via administration of the antibody, facilitating the study of immune responses in the absence of helper T cells. This depletion strategy allows researchers to assess the specific contributions of CD4 T cells to disease models, vaccine efficacy, and immune regulation.

• Epitope Specificity: OX-38 recognizes a distinct epitope on rat CD4 that differs from other commonly used anti-CD4 clones, such as W3/25 and OX-35. This specificity can be crucial for experimental design and interpreting results in flow cytometry or functional studies.

• Application in Flow Cytometry: OX-38 is frequently employed in flow cytometry to identify, sort, or quantify rat CD4+ T cells. It is available in conjugated forms (such as PE-Cy7 or FITC) designed for multiparametric analysis of immune cell populations.

• Comparison with Other Anti-CD4 Clones: OX-38 is often discussed alongside other monoclonal antibodies (e.g., W3/25, GK1.5, RM4-4, RM4-5), which differ in species reactivity and epitope recognition. Selection of OX-38 is recommended where its specificity for rat CD4 domain 1 is required.

• Role in Immunological Experiments: OX-38 citations typically involve studies on rat immune function, autoimmunity, infection models, transplant biology, or vaccine studies, where manipulation or identification of CD4+ T cell populations is essential.

In summary, the antibody clone OX-38 is a key reagent for studying the function and dynamics of CD4+ T cells in rat models through depletion or detection, with its unique epitope specificity making it valuable for research requiring precise targeting of the CD4 molecule.

Dosing regimens for clone OX-38 (a rat anti-mouse CD4 monoclonal antibody) can vary across different mouse models based on factors such as the experimental aim (e.g., immune cell depletion vs. functional blocking), mouse strain, and disease context. However, detailed peer-reviewed dosing references specifically for OX-38 are limited in the provided results; the search produced more data on other monoclonal antibodies, such as anti-CD3, anti-PD-1, and OX-86 (anti-CD134).

Key context and supporting details:

• Most in vivo antibody dosing guides recommend administering depleting or blocking monoclonal antibodies via intraperitoneal (i.p.) injection, typically at standard doses ranging from 100–500 μg per mouse for other rat anti-mouse antibodies, with schedules of every 3–7 days depending on the study design and biological endpoint.
• Dosing regimens may be modified based on mouse strain. For example, nude mice (which lack T cells) often require adjusted timing or frequency due to altered tumor growth kinetics or differential immune responses compared to immunocompetent strains.
• For antibodies of similar isotype and function to OX-38 (e.g., OX-86, an anti-CD134 rat IgG1), a typical regimen is 0.25 mg (250 μg) intraperitoneally, once daily for 3–7 consecutive days.
• Fixed dosing (a set amount per mouse) is often preferred to mg/kg dosing for monoclonal antibodies in oncology, as antibody pharmacokinetics are less dependent on body weight and fixed dosing reduces variability between animals.

Points to consider for OX-38 in different mouse models:

• Strain and immunocompetence: Sensitive strains or immunodeficient mice may require lower or less frequent doses to avoid toxicity or off-target effects.
• Experimental endpoint: Depletion studies (such as CD4+ T cell removal) may require repeated or higher doses compared to transient blocking studies.
• Route of administration: Intraperitoneal is standard, but intravenous and subcutaneous routes are sometimes used, typically with comparable dosing.
• Literature-specific regimens: Although direct dosing data on OX-38 was not found in this search, published studies with closely related antibodies and standard dosing guides are typically referenced to set initial dosing parameters, which are then optimized per model and experiment.

If you require dosing for a specific disease model or experimental goal, searching for peer-reviewed literature referencing OX-38 in that precise context is advisable. When in doubt, start with established dosing (e.g., 200–500 μg i.p. every 3–7 days) and monitor for efficacy and toxicity, adjusting based on observed effects and study needs.

Summary table for context:

*Estimated for OX-38 based on similar antibodies; confirm in pilot studies or relevant literature.

If you need precise, model-specific OX-38 regimens, direct primary references will yield the most reliable dosing information.